Uncategorized
Additional milestone payment made from Valeant to EyeGate for EGP-437
EyeGate Pharmaceuticals has received an additional milestone payment from Valeant Pharmaceuticals for worldwide commercial and manufacturing rights to its EyeGate II delivery system and EGP-437 combination product for uveitis, according to an EyeGate press release.A total of $32.5 million in payments is possible for development-based and commercial milestones under the license agreement between the two entities.